Cargando…

Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation

Dipeptidyl peptidase-4 (DPP-4) is the vital enzyme that is responsible for inactivating intestinal peptides glucagon like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP), which stimulates a decline in blood glucose levels. The aim of this study was to explore the inhibition activity of sm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meduru, Harika, Wang, Yeng-Tseng, Tsai, Jeffrey J. P., Chen, Yu-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926453/ https://www.ncbi.nlm.nih.gov/pubmed/27304951 http://dx.doi.org/10.3390/ijms17060920

Ejemplares similares

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes
por: Zilleßen, Pia, et al.
Publicado: (2016)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
por: Barchetta, Ilaria, et al.
Publicado: (2022)

Structure–Activity Relationship and Molecular Docking of Natural Product Library Reveal Chrysin as a Novel Dipeptidyl Peptidase-4 (DPP-4) Inhibitor: An Integrated In Silico and In Vitro Study
por: Kalhotra, Poonam, et al.
Publicado: (2018)

Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity
por: Hoshino, Yuki, et al.
Publicado: (2022)

Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study
por: Arulmozhiraja, Sundaram, et al.
Publicado: (2016)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19
por: Firneisz, Gábor
Publicado: (2023)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Neuronal Roles of the Multifunctional Protein Dipeptidyl Peptidase-like 6 (DPP6)
por: Malloy, Cole, et al.
Publicado: (2022)

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus
por: Cui, Jie, et al.
Publicado: (2013)

The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice
por: Takeda, Kenichiro, et al.
Publicado: (2018)

Reply to Firneisz: “Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19”
por: Lin, Shu-Hai, et al.
Publicado: (2023)

The effect of Dipeptidyl peptidase 4 (DPP-4) inhibitors on hemoglobin level in diabetic kidney disease: A retrospective cohort study
por: Zeng, Lingfeng, et al.
Publicado: (2023)

Identification of Dipeptidyl-Peptidase (DPP)5 and DPP7 in Porphyromonas endodontalis, Distinct from Those in Porphyromonas gingivalis
por: Nishimata, Haruka, et al.
Publicado: (2014)

Identification of Potential Dipeptidyl Peptidase (DPP)-IV Inhibitors among Moringa oleifera Phytochemicals by Virtual Screening, Molecular Docking Analysis, ADME/T-Based Prediction, and In Vitro Analyses
por: Yang, Yang, et al.
Publicado: (2020)

Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients
por: Sarkar, Jit, et al.
Publicado: (2019)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

The Inhibitory Effects of New Zealand Pine Bark (Enzogenol(®)) on α-Amylase, α-Glucosidase, and Dipeptidyl Peptidase-4 (DPP-4) Enzymes
por: Lim, Wen Xin Janice, et al.
Publicado: (2022)

Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease
por: Algaissi, Abdullah, et al.
Publicado: (2019)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin
por: Chittepu, Veera C. S. R., et al.
Publicado: (2019)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects
por: Krishna, Rajesh, et al.
Publicado: (2016)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Therapy in the Management of Latent Autoimmune Diabetes in Adults (LADA): A Systematic Review and Meta Analysis
por: Alanes Escueta, Luz Margaret, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
por: Zein, Ahmad Fariz Malvi Zamzam, et al.
Publicado: (2022)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Circulating dipeptidyl peptidase (cDPP3)—A marker for end‐stage heart failure?
por: Pavo, Noemi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mh44qvptui42gujcm98cksp36u